Trial · NCT07910019
Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
NCT07910019, Recruiting, Masonic Cancer Center, University of Minnesota
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers. Trials, record NCT07910019. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910019
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
- NCT number
- NCT07910019
- Status
- Recruiting
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Prostate Carcinoma
- Interventions
- Non-Interventional Study
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Baseline natural cytotoxicity of CSPC and CRPC patients' natural killer cells | Through study completion, an average of 1 year | Will be evaluated against K562 cells (to which NK cells actively degranulate and kill without cytokine or engager) and prostate cancer cell lines (C4-2, PC3, DU145, and 22RV1) using standard in vitro assays. CSPC and CRPC patient NK cells collected will be compared to age- and race-matched normal donor NK cells, which are a by-product of blood donation. Data will be summarized using descriptive statistics and pairwise comparisons with two-sided paired t-tests. |
| Primary | Broad immune landscape | Through study completion, an average of 1 year | Mass cytometry will be used to explore the broad immune landscape. CyTOF (Fluidigm), or mass cytometry, is a variation of flow cytometry in which antibodies are labeled with heavy metal ion tags instead of fluorochromes. Readout is by time-of-flight mass spectrometry. The research team have developed and validated a complex NK cell-focused panel containing 42 antibodies to track NK cell characteristics in patient or lab samples. This panel also includes B7H3, to help track potential expression of the target antigen on myeloid cells. The panel allows for in-depth understanding of differences in circulating NK cells from patients of different races versus matched normal donors. Descriptive statistics will be used for comparisons between features of peripheral blood and tissue biopsy samples when applicable. |
| Primary | Analysis of biopsy samples | Through study completion, an average of 1 year | Existing patient biopsy samples from the time of diagnosis will be analyzed using a multiplex immunofluorescence panel with the CODEX platform specifically designed for analysis of prostate cancer infiltrating immune fractions. Descriptive statistics will be used for comparisons between features of peripheral blood and tissue biopsy samples when applicable. |
| Primary | Effects on NK cells treated with IL-15, camB7-H3 TriKE, scFv PSMA TriKE, or camB7-H3/PSMA TriKE-PACC | Through study completion, an average of 1 year | Will use descriptive statistics to evaluate effects on NK cells treated with IL-15, camB7-H3 TriKE, scFv PSMA TriKE, or camB7-H3/PSMA TriKE-PACC. |
| Primary | Ability of the 5 treatments to mitigate tumor burden | Through study completion, an average of 1 year | For the tumor control studies, the ability of the 5 treatments to mitigate tumor burden will be assessed by tumor volume over time. We will compare the differences in tumor volumes on days 21 and 35 across the 3 different groups using repeated measures analysis of variance models and t-tests for pairwise comparisons. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910019
GET https://conductscience.org/api/trials/v1/NCT07910019/registered